Published in J Affect Disord on March 07, 2006
Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol (2007) 3.06
Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav (2011) 1.38
Association of psychiatric and substance use disorder comorbidity with cocaine dependence severity and treatment utilization in cocaine-dependent individuals. Drug Alcohol Depend (2008) 1.04
Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation. Neuropsychopharmacology (2011) 0.97
The role of lamotrigine in the management of bipolar disorder. Neuropsychiatr Dis Treat (2007) 0.84
HCN Channel Targets for Novel Antidepressant Treatment. Neurotherapeutics (2017) 0.79
Treatment development and feasibility study of family-focused treatment for adolescents with bipolar disorder and comorbid substance use disorders. J Psychiatr Pract (2014) 0.78
Assessment of depressive symptom severity among patients with co-occurring bipolar disorder and substance dependence. J Affect Disord (2007) 0.76
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA (2003) 34.83
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA (2006) 6.26
Medication augmentation after the failure of SSRIs for depression. N Engl J Med (2006) 5.16
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am (2003) 5.05
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry (2008) 4.98
Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A (2007) 3.92
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry (2006) 3.90
Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry (2008) 3.40
Estimating Individualized Treatment Rules Using Outcome Weighted Learning. J Am Stat Assoc (2012) 3.13
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry (2006) 2.90
Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry (2007) 2.87
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry (2007) 2.84
Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. Am J Psychiatry (2011) 2.58
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A (2003) 2.56
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet (2006) 2.55
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry (2005) 2.50
STAR*D: what have we learned? Am J Psychiatry (2007) 2.47
Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. Am J Psychiatry (2008) 2.42
A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry (2006) 2.21
Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. JAMA (2010) 2.16
Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. Am J Psychiatry (2004) 2.11
The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep (2007) 2.08
Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. J Psychiatr Res (2013) 1.99
Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. J Clin Psychiatry (2005) 1.99
Methodological challenges in constructing effective treatment sequences for chronic psychiatric disorders. Neuropsychopharmacology (2006) 1.93
Early physical and sexual abuse associated with an adverse course of bipolar illness. Biol Psychiatry (2002) 1.93
Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry (2006) 1.90
Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract (2006) 1.89
Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry (2007) 1.88
The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry (2008) 1.86
Genome-wide association study of suicide attempts in mood disorder patients. Am J Psychiatry (2010) 1.85
Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. Am J Psychiatry (2010) 1.82
Gender differences in depression: findings from the STAR*D study. J Affect Disord (2005) 1.80
Prevalence of major depressive episode in CKD. Am J Kidney Dis (2009) 1.79
Effect of age at onset on the course of major depressive disorder. Am J Psychiatry (2007) 1.78
What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv (2009) 1.77
Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? J Clin Psychiatry (2005) 1.76
Obsessive compulsive symptoms in schizophrenia: frequency and clinical features. Schizophr Res (2005) 1.75
Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry (2004) 1.75
Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry (2003) 1.72
Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. J Clin Psychiatry (2008) 1.70
Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J Clin Psychiatry (2005) 1.70
Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. Acta Psychiatr Scand (2009) 1.67
Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry (2007) 1.67
Measurement-based care in psychiatric practice: a policy framework for implementation. J Clin Psychiatry (2011) 1.65
Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry (2002) 1.65
Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med (2004) 1.64
Customizing treatment to the patient: adaptive treatment strategies. Drug Alcohol Depend (2007) 1.63
Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am J Psychiatry (2013) 1.61
Relief of expressed suicidal intent by ECT: a consortium for research in ECT study. Am J Psychiatry (2005) 1.61
15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry (2005) 1.60
Drug dreams in outpatients with bipolar disorder and cocaine dependence. J Nerv Ment Dis (2004) 1.59
The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol (2006) 1.58
Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry (2005) 1.57
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J Clin Psychiatry (2008) 1.57
Children of currently depressed mothers: a STAR*D ancillary study. J Clin Psychiatry (2006) 1.57
Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo. Arch Gen Psychiatry (2002) 1.55
Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry (2002) 1.55
A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res (2005) 1.55
A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry (2013) 1.53
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry (2007) 1.53
Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry (2007) 1.53
Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry (2004) 1.53
The impact of nonclinical factors on care use for patients with depression: a STAR*D report. CNS Neurosci Ther (2009) 1.49
The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry (2002) 1.49
Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry (2003) 1.48
A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry (2005) 1.48
High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry (2002) 1.48
On the psychometric validity of the domains of the PDSQ: an illustration of the bi-factor item response theory model. J Psychiatr Res (2008) 1.47
Impact of structured clinical interviews on physicians' practices in community mental health settings. Psychiatr Serv (2003) 1.46
International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials (2011) 1.46
Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data. J Clin Psychiatry (2007) 1.45
The efficacy of acute electroconvulsive therapy in atypical depression. J Clin Psychiatry (2008) 1.44
Evaluating the impact of pharmacists in mental health: a systematic review. Pharmacotherapy (2003) 1.44
Validation of depression screening scales in patients with CKD. Am J Kidney Dis (2009) 1.43
A descriptive analysis of minor depression. Am J Psychiatry (2002) 1.40
New designs for studies of the prophylaxis of bipolar disorder. J Clin Psychopharmacol (2002) 1.39
Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. Neuropsychopharmacology (2007) 1.39
Hippocampal volumes in youth with type 1 diabetes. Diabetes (2009) 1.38
Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry (2009) 1.38
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry (2004) 1.35
Frequency and timing of severe hypoglycemia affects spatial memory in children with type 1 diabetes. Diabetes Care (2005) 1.34
Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry (2006) 1.33
Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology (2008) 1.29
Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry (2010) 1.29
National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry (2002) 1.29
Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med (2008) 1.28
Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol Psychiatry (2004) 1.28
Constructing evidence-based treatment strategies using methods from computer science. Drug Alcohol Depend (2007) 1.26
The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. Schizophr Res (2008) 1.26
Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry (2006) 1.25
Implementing practice guidelines for depression: applying a new framework to an old problem. Gen Hosp Psychiatry (2002) 1.25
Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. Drug Alcohol Depend (2008) 1.24
Sertraline as a first-line treatment for cholestatic pruritus. Hepatology (2007) 1.24
Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv (2007) 1.23
What predicts attrition in second step medication treatments for depression?: a STAR*D Report. Int J Neuropsychopharmacol (2008) 1.23
Dropouts versus completers among chronically depressed outpatients. J Affect Disord (2006) 1.22
Factors that differentiate early vs. later onset of major depression disorder. Psychiatry Res (2004) 1.21